Idanuz (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the action of bradykinin, a peptide that causes vasodilation and increased vascular permeability, thereby preventing the swelling associated with hereditary angioedema attacks.

The dosage of Idanuz is determined by the prescribing healthcare professional based on the patient’s condition, severity of the attack, and clinical guidelines. The prescriber decides the amount and timing of each subcutaneous injection, and patients should follow the exact instructions provided.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after evaluating the individual situation.

To request Idanuz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Idanuz (icatibant) is a bradykinin B2 receptor antagonist, whereas alternative therapies such as C1‑inhibitor concentrates replace the deficient protein, and newer agents like lanadelumab are monoclonal antibodies targeting plasma kallikrein. Icatibant offers rapid subcutaneous administration and acts directly on the bradykinin pathway, providing a distinct mechanism of action.

Idanuz should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the product. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration; discard if any abnormalities are observed.

Idanuz is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient using the supplied pre‑filled syringe or autoinjector. Proper aseptic technique and correct site rotation help minimize injection‑site reactions.

The most serious risks include severe hypotension, anaphylactic reactions, and rare cases of injection‑site necrosis. Patients should be monitored for signs of systemic allergic response, sudden drop in blood pressure, or worsening swelling, and seek immediate medical attention if any of these occur.

Idanuz is contraindicated in individuals with known hypersensitivity to icatibant or any of the formulation components. It should also be avoided in patients who have experienced severe anaphylactic reactions to the drug and in those for whom alternative approved therapies are more appropriate, as determined by a healthcare professional.